Insulet (NASDAQ:PODD) Announces Earnings Results

Insulet (NASDAQ:PODD) issued its earnings results on Thursday. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11, Zacks reports. The firm had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s revenue was up 29.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.08 earnings per share. Insulet updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Insulet Stock Down 1.1%

PODD traded down $3.58 during trading on Friday, hitting $319.82. The stock had a trading volume of 677,166 shares, compared to its average volume of 721,278. The stock has a 50 day simple moving average of $325.06 and a two-hundred day simple moving average of $309.40. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet has a twelve month low of $230.05 and a twelve month high of $353.50. The company has a market capitalization of $22.51 billion, a PE ratio of 97.21, a PEG ratio of 2.64 and a beta of 1.39.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Raymond James Financial raised their target price on shares of Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a research report on Friday. Canaccord Genuity Group lifted their target price on Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research report on Friday. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Wolfe Research increased their target price on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $370.76.

Insider Buying and Selling at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Osterweis Capital Management Inc. acquired a new stake in shares of Insulet during the second quarter worth $51,000. NewEdge Advisors LLC raised its stake in Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 64 shares during the last quarter. MUFG Securities EMEA plc acquired a new stake in Insulet during the 2nd quarter worth about $65,000. Teza Capital Management LLC purchased a new stake in Insulet during the 2nd quarter valued at about $223,000. Finally, State of Wyoming increased its holdings in shares of Insulet by 91.5% in the second quarter. State of Wyoming now owns 923 shares of the medical instruments supplier’s stock valued at $290,000 after purchasing an additional 441 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.